Core Insights - The report maintains a positive outlook on the pig farming industry, recommending continued investment in pig farming despite recent price declines due to supply pressures [1][7][21] - The report highlights a significant drop in pig prices, with the average price for market pigs at 12.67 yuan/kg, down 3.65% week-on-week [7][32][33] - The report indicates ongoing losses in pig farming, with self-breeding and purchased pig farming yielding losses of 74.11 yuan/head and 236.57 yuan/head respectively [7][37] Industry Overview - The agricultural sector index has decreased by 1.97% week-on-week, while the Shanghai and Shenzhen 300 index increased by 1.07% [11] - Since January 2, 2025, the agricultural sector has seen a total increase of 16.95%, compared to a 15.63% increase in the Shanghai and Shenzhen 300 index [12][11] - The report notes that the pig farming sector is currently in a downward cycle, with supply pressures gradually being released [21] Pig Farming Data Tracking - The number of breeding sows has slightly decreased by 0.80% month-on-month in August, indicating a potential reduction in future supply [22][7] - The average weight of market pigs at the time of sale is reported at 128.55 kg [22][8] - The report emphasizes that the current breeding and purchasing sentiment is declining due to stricter environmental regulations and market conditions [17][21] Poultry Farming Data Tracking - The average price for white feathered chickens is reported at 6.90 yuan/kg, with a slight increase of 0.29% week-on-week [38][41] - The report notes that the poultry industry is facing uncertainties due to ongoing outbreaks of avian influenza in overseas markets [38][39] Animal Health Data Tracking - The demand for animal health products is expected to rebound, with significant growth in vaccine approvals and product launches [46] - The report highlights that the industry is seeing a recovery in sales, with some vaccines showing substantial year-on-year growth [46] Seed Industry Data Tracking - The average prices for wheat, soybean meal, and corn have shown slight increases, indicating a potential upward trend in agricultural input costs [50] - The report emphasizes the importance of food security and the need for advancements in agricultural biotechnology [50] Pet Industry Data Tracking - Pet food exports have decreased by 15.5% year-on-year, with a total export value of 834 million yuan in August 2025 [55][56] - Domestic sales of pet food continue to grow, with significant increases reported on e-commerce platforms [57] - The report suggests that companies with strong domestic sales and innovative product offerings are likely to gain market share [59]

Core Viewpoint - The company announced a change in the use of part of the funds raised from a specific stock issuance in 2021, redirecting them towards the construction of a "Biomanufacturing Industrialization Project" [1] Group 1 - The company held its 27th (temporary) meeting of the fifth board of directors on September 28, 2025, to review the proposal [1] - The proposal to change the use of funds requires approval from the company's shareholders' meeting [1]

Core Insights - The animal health sector experienced a slight increase of 0.46% on September 29, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Stock Performance - Shenlian Biological (688098) closed at 10.59, up 1.92% with a trading volume of 68,700 shares and a turnover of 72.32 million yuan [1] - Other notable performers included: - Biological Shares (600201) at 9.48, up 1.50% with a turnover of 503 million yuan [1] - Pulaike (603566) at 13.78, up 1.03% with a turnover of 54.30 million yuan [1] - Zhongmu Shares (600195) at 7.12, up 0.85% with a turnover of 49.02 million yuan [1] Capital Flow - The animal health sector saw a net outflow of 7.69 million yuan from institutional investors, while retail investors contributed a net inflow of 8.08 million yuan [2] - The detailed capital flow for key stocks includes: - Shenlian Biological: net outflow of 5.50 million yuan from retail investors [3] - Biological Shares: net outflow of 7.67 million yuan from retail investors [3] - Pulaike: net outflow of 4.08 million yuan from retail investors [3]

Core Viewpoint - The company plans to allocate a total of 160 million yuan from the "South China Biological Large-Scale Suspension Culture Workshop Construction Project" and 115 million yuan from the remaining funds of the "Zhong'an Biological Expansion and Renovation Project" to the "Biomanufacturing Industrialization Engineering Construction Project" [1] Group 1 - The total investment for the new project is 679 million yuan, with 296 million yuan sourced from raised funds [1] - The implementation entities for the new investment project are the company and its wholly-owned subsidiary, Tianjin Ruishi Biotechnology Co., Ltd [1] - The project will be located in the Tianjin Port Free Trade Zone, Lingang area [1] Group 2 - The raised funds include 20.8231 million yuan from interest income and financial management returns, which will be deducted from the total amount [1] - The remaining investment will be financed through the company's own funds or self-raised funds [1]

关于瑞普生物股份有限公司 中国银河证券股份有限公司 变更部分募集资金用途 的核查意见 瑞普生物股份有限公司（以下简称"公司""瑞普生物"）于 2025 年 9 月 28 日 召开第五届董事会第二十七次（临时）会议，审议通过了《关于变更部分募集资金用 途的议案》，同意公司变更 2021 年向特定对象发行股票部分募集资金投资项目用途， 用于建设"生物制造产业化工程建设项目"，该议案已经公司第五届监事会第二十三 次（临时）会议审议通过，尚需提交公司股东大会审议。 中国银河证券股份有限公司（以下简称"银河证券"或"保荐人"）作为瑞普生 物 2021 年度向特定对象发行股票的保荐人，根据《证券发行上市保荐业务管理办法 （2025 修正）》《深圳证券交易所创业板股票上市规则（2025 年修订）》《深圳证 券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作（2025 年修订）》 《上市公司募集资金监管规则》等相关规定，对公司变更部分募集资金用途事项进行 了审慎核查，具体核查情况和核查意见如下： 一、改变募集资金投资项目的概述 （一）募集资金基本情况 经中国证券监督管理委员会于 2021 年 9 月 10 日下 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-076 瑞普生物股份有限公司（以下简称"公司""瑞普生物"）于 2025 年 9 月 28 日召开第五届董事会第二十七次（临时）会议，审议通过了《关于变更部分 募集资金用途的议案》，同意公司变更 2021 年向特定对象发行股票部分募集资 金投资项目用途，用于建设"生物制造产业化工程建设项目"，该议案尚需提交 公司股东大会审议。 现将具体情况公告如下： 一、改变募集资金投资项目的概述 （一）募集资金基本情况 经中国证券监督管理委员会于 2021 年 9 月 10 日下发的《关于同意天津瑞普 生物技术股份有限公司向特定对象发行股票注册的批复》（证监许可〔2021〕2974 号），同意公司向特定对象发行人民币普通股（A 股）63,984,674 股，发行价格 为人民币 20.88 元/股，募集资金总额为人民币 1,335,999,993.12 元，扣除各项发 行 费 用 （ 不 含 税 ） 人 民 币 13,979,522.73 元 后 ， 募 集 资 金 净 额 为 人 民 币 1,322,020,470.39 元。 上述募集资金于 2021 年 1 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-077 瑞普生物股份有限公司 关于召开 2025 年第五次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本次股东大会召开的基本情况 1、股东大会届次：2025年第五次临时股东大会 2、会议召集人：经公司第五届董事会第二十七次（临时）会议审议通过， 公司董事会决定召开2025年第五次临时股东大会。 3、会议召开的合法、合规性：本次股东大会的召集程序符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开时间： 5、会议的召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 现场会议召开时间：2025 年 10 月 15 日（星期三）14:30 （1）现场投票：包括本人出席及通过填写授权委托书授权他人出席。 网络投票时间为： （2）网络投票：公司将通过深圳证券交易所交易系统和互联网投票系统向 股东提供网络形式的投票平台，公司股东应在本通知列明的有关时限内通过深圳 证券交易所的交易系统或互联网投票系统进行网络投票。 通过深圳证券交易所交易系统进行 ...

Core Viewpoint - The company plans to allocate a total of 160 million yuan from the "South China Biological Large-Scale Suspension Culture Workshop Construction Project" and 115 million yuan from the surplus funds of the "Zhong'an Biological Renovation and Expansion Project" to the "Biomanufacturing Industrialization Engineering Construction Project" [1] Group 1 - The total investment for the new project is 679 million yuan, with 296 million yuan sourced from raised funds [1] - The implementation entities for the new investment project are the company and its wholly-owned subsidiary, Tianjin Ruishi Biotechnology Co., Ltd [1] - The project will be located in the Tianjin Port Free Trade Zone, Lingang area [1] Group 2 - The raised funds include 20.8231 million yuan from financial management income and interest income [1] - The remaining investment will be funded through the company's own funds or self-raised funds [1]

证券代码：300119 证券简称：瑞普生物 公告编号：2025-075 瑞普生物股份有限公司 第五届监事会第二十三次（临时）会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、监事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届监事会第二十三次（临 时）会议于 2025 年 9 月 28 日在公司会议室以现场表决方式召开。会议通知于 2025 年 9 月 26 日以书面及电子邮件等方式送达全体监事。公司应出席监事 3 人， 实际出席监事 3 人，参与表决监事 3 人。本次会议由监事会主席周仲华先生主持。 本次会议的召集、召开和表决程序符合《公司法》《证券法》等法律法规和《公 司章程》的规定。 二、监事会会议审议情况 1、审议通过了《关于变更部分募集资金用途的议案》 经审议，监事会认为公司本次变更募集部分资金用途事项符合《上市公司募 集资金监管规则》及《深圳证券交易所上市公司自律监管指引第2号——创业板 上市公司规范运作》等相关规定，有利于提升募集资金使用效率，不存在损害股 东特别是中小股东利益的情况。该事项决策和审议程序合法、合规， ...

瑞普生物股份有限公司 第五届董事会第二十七次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 瑞普生物股份有限公司（以下简称"公司"）第五届董事会第二十七次（临 时）会议于 2025 年 9 月 28 日在公司会议室以现场结合通讯表决方式召开。会议 通知于 2025 年 9 月 26 日以书面及电子邮件等方式送达全体董事。公司应出席董 事 9 人，实际出席董事 9 人（其中：董事杨鶄、李睿，独立董事才学鹏、郭春林 以通讯方式参会），参与表决董事 9 人。本次会议由董事长李守军先生主持，公 司高级管理人员列席了会议。本次会议的召集、召开和表决程序符合《公司法》 《证券法》等法律法规和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过了《关于变更部分募集资金用途的议案》 经审议，为加快推进公司在生物制造领域的战略布局，提升募集资金使用效 率，切实维护股东利益，董事会同意公司将"华南生物大规模悬浮培养车间建设 项目"全部拟投入募集资金 1.60 亿元及"中岸生物改扩建项目"中节余募集资 金 1.15 亿元及上述两个 ...